The 3 Things That Matter for Viking Therapeutics Now

Investing successfully in biopharmaceutical companies can sometimes require complicated calculations worthy of Albert Einstein's brain. That's because picking the right ones involves a variation of the theory of relativity. And that's tied to the notion that the battle for sales is won not only in the marketing field, but also in who has the most promising clinical trial data. Differing forces can have a relative impact on which company succeeds.As such, investors interested in Viking Therapeutics (NASDAQ: VKTX) need to monitor not only that company's weight loss drug development but also the development pipelines of rivals Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). Effectively, all three things matter when it comes to the investment thesis for Viking. Here's why.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool